Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Merck you know what you got to do right?
Wow thanks Sox. Good info makes one wonder what the comparators are?
Thanks for giving away my secret beef jerky recipe away
Bobby they are not going to recover any money and just end up paying the lawyers a lot more.
505b2 is Huge! We only need to show efficacy... safety is already established.
Great what are the normal levels of IL-20 and did Prurisol return those levels to normal? My office is right next to a nude mice lab but all I see are the weird lab techs that replace the bedding.
Sun, you might have some confusion about what a xenograft is with nude mice. Once the graft is applied it becomes part of the mouse supported by the mouse. The nude mice have been genetically altered not to reject the graft. If the graft failed which it could do it would be a failed graft with an obvious appearance and surely would not have the appearance of the mice in the treated group.
After the graft the mouse has psoriasis. Look at the bar charts for Prins and IL-20 are these measured in the blood of the mouse or just somehow in the graft???? Trying to distinguish the mouse from the graft does not make sense to me..they would be one and the same.
As far as using the word "cure" is always tricky anywhere, but looking at the reduction in serum levels of IL and Prins it is significant.
Time will tell..
I think it was the second week of the month.
With long awaited Kevetrin data coming up we should have no problem breaking two. Heck back in 2013 when all we had was Kevetrin in the early cohorts we were at ~two and minimal dilution since. All signs are the safety is fantastic and efficacy even in a dose-ranging study appears to be there as well.
And now we got Brilacidin ABX going in to phase 3. Prurisol will likely complete enrollment by year end. Kevetrin AML at last? Brilacidin-OM active we will move up I am not sure even the stinky-pinkies can stop that. I also suspect we will get back a lot of "old" investors sometime after Nov. 2nd.
Looking good, if anyone was interested in selling for a tax-loss they should have already did it.
Thanks Easyrider, the trials patient-wise are smaller than what i was thinking. I thought they would be around 1500 patients each not 1400 for both. Save money and a quicker sounds good to me. With interium trial results on the first trial.
4 months for a pancreatic patient is impressive!
Sox, my thoughts too
If the FDA approves it ...it must be true! Watermelon is another favorite...look out we just lost Prurisol!
The FDA can approve lollipops for treatment pancreatic. The treatment that will be used will be one that is safest and most efficacous. Just because they approve something it doesn't mean its just beat out Kevetrin.
With my example coupled with your apparent logic lollipops have just KO'd Kevetrins chances.
Those green apple charm pops are the bomb IMO
With less than 2 months increase in survival I think we can all hope Kevetein can top that.
Looks like Kevetrin is in lead. Nutlins are toxic the company has been searching for years to find an application where thats not true. The other phase1 I have not heard of. The big thing/challenge with reactivating p53 in my view is doing so without toxicity Kevetrin appears to have resounding success here. With signs of efficacy in ovarian, pancreatic and thyroma in phase 1 dose esculation study. I cannot wait to see wait to see what happens in these phase 2 studies with a optimized dosing. Kevetrin clears quickly out of the body increasing dosing frenquency will be interesting!
We also get to see K tackle blood cancers at optimized doses which is likely to occur before the phase 2 solid tumors.
Hopefully Dr. Menon and family have not suffered any adverse events. I was not anticipating the event to be a big catalyst for the co. more like spreading the word.
What did they say about the schedule change?
Nice post NR. I think and in some ways sadly our next catalyst driving us back up to $2 might be finding out what are big law firm is going to do to Rosen and hopefully Mako.
He should say exactly that then drop the mic and walk away!
Looking forward to a Kevetrin update.
The other at the appropriate time will announce its fund raising desires. One problem with rs "raise money while you can" that is why Leo is not desperate to uplist funding is already in place. The other did a rs then uplist then fund raise/dilution with no fs. Whatever great news is about to come out is already largely baked into the share price. I like Leo's method better the only problem was that crazy hit piece.
Elephants have somethnig like 38 copies of tp53.
LOL ctix should be on the rise soon then.
Cabel I only recall the 60 days for the pediatric plan for Brilacidin. Once they submit their phase 3 design for ABX the FDA has 30 days??? to respond.
Well CTIX doesn't have patent concerns like the other one does.
Sox, don't break out the black light we are going need you to stay at the Holiday Inn a few more nights
Asta, nicely put. Especially liked the last sentence.
Wow, John Ashcroft. I remember him from his political days.
NR, I do not recall any PR's in advance detailing any trial designs of any of the trials we have had so far. Typically, I read the specifics from the FDA page. When the study is about to start or has started abbreviated trial designs show up in the companies PRs. I like you am curious with the specifics of our first phase 3 but it may elude the company to share those details with investors.
Hey 58, I figured out how I can use Alan's data. So 40% of todays volume was from MM's and the rest was retail?
Thanks Alan! At last I know the MM volume and I can use this information to....ahhh
Hey Alan, does FINRA really use the exclamation point when officially reporting your short sale volumes!!!
Great news on Prurisol enrollment and with no AE's it sounds like treatment (at last) has begun....woot.
No mention of B-OM enrollment but this one will take time.
Looking forward to see Brilacidin p3 plans and anything from Kevetrin..expecting another orpan drug indication here.
You can see why they ordered 30 lbs API of Brilacidin it takes a while to manfactor it. The update here is just a follow up on the PR a while back when they informed us they were ordering it. Good to plan ahead. Its not a repeat of the same info rather the progress.
Aruda, if that is you sell them all lets get this over with!
Its the AVXX. Effect
Must be a juicy PR coming Monday!
Operation history with the second audited 10k without it we needed $4
Anyone believe that will allow some of multiple-cohort patients to continue Kevetrin treatment after the Harvard phase 1 clinical trial?
Kind of beating a dead horse there with the r/s talk. Just not going to happen.